Middle East and Turkey Hemophilia Treatment Market, By Product Type (Recombinant Coagulation Factor, Plasma Derived Coagulation Factor, Antifibrinolytic Agents, and Desmopressin), By Disease Indication (Hemophilia A, Hemophilia B, and Hemophilia C), and B

Middle East and Turkey Hemophilia Treatment Market, By Product Type (Recombinant Coagulation Factor, Plasma Derived Coagulation Factor, Antifibrinolytic Agents, and Desmopressin), By Disease Indication (Hemophilia A, Hemophilia B, and Hemophilia C), and By Country (Turkey, Egypt, Israel, Saudi Arabia, UAE, and Rest of Middle East)- Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

Hemophilia is rare disorder, in which the blood does not clot properly, and Bleeding after an injury takes longer duration to clot. This condition is well treated with medications such as recombinant coagulation factor, plasma derived coagulation factor, antifibrinolytic agents, and desmopressin. Generally hemophilia occurs in middle age and geriatric population, and in women after child birth. Hemophilia is characterized by the lower levels of factors in the blood that results in constant bleeding for longer duration after an injury.

Market Dynamics

Increasing adoption of inorganic growth strategies such as partnership by key market players, in order to expand their product portfolio, is expected to drive the market growth over the forecast period. For instance, in March 2021, Takeda Pharmaceutical Company Limited., a pharmaceutical company, announced it had entered into a strategic partnership with Enzyre, developer of diagnostic technology, to accelerate the development of Enzyre’s proprietary platform named Enzypad to enable patients to test their blood coagulationat their home.

Increasing adoption of organic growth strategies such product launches by key market players, in oder to expand their product portfolio is expected to drive the market growth over the forecast period. For instance, in November 2022, UniQure, a pharmaceutical company, announced the U.S. Food and Drug Administration approved the first gene therapy Hemgenix for the treatment of adults with hemophilia B that is currently used in factor IX prophylaxis therapy, or has current or historical life-threatening hemorrhage. Hemophilia B is a rare, lifelong bleeding disorder caused by a single gene defect that results in insufficient production of factor IX, a protein produced by the liver that aids in the formation of blood clots.

Key features of the study:

• This report provides in-depth analysis of the Middle East and Turkey hemophilia treatment market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2023–2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the Middle East and Turkey hemophilia treatment market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study are Takeda Pharmaceutical Company Limited., Sanofi S.A., Octapharma AG, Swedish Orphan Biovitrum AB, Baxter International Inc., Biogen Inc., Bayer AG, CSL Behring, Ferring B.V., Pfizer, Inc., Kedrion, Novo Nordisk A/S, Grifols S.A., Sangamo Therapeutics, Inc., and Spark Therapeutics, Inc.
• Insights from this report will allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Middle East and Turkey hemophilia treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Middle East and Turkey hemophilia treatment market

Detailed Segmentation:

• Middle East and Turkey Hemophilia Treatment Market, By Product Type
• Recombinant Coagulation Factor
• Plasma Derived Coagulation Factor
• Antifibrinolytic Agents
• Desmopressin
• Middle East and Turkey Hemophilia Treatment Market, By Disease Indication
• Hemophilia A
• Hemophilia B
• Hemophilia C
• Middle East and Turkey Hemophilia Treatment Market, By Country
• Turkey
• Egypt
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East
• Company Profiles
• Takeda Pharmaceutical Company Limited.*
• Company Highlights
• Products Portfolio
• Key Highlights
• Financial Performance
• Strategies
• Sanofi S.A.
• Octapharma AG
• Swedish Orphan Biovitrum AB
• Baxter
• Biogen Inc.
• Bayer AG
• CSL Behring
• Ferring B.V.
• Pfizer, Inc.
• Kedrion
• Novo Nordisk A/S
• Grifols S.A.
• Sangamo Therapeutics, Inc.
• Spark Therapeutics, Inc.

“*” marked represents similar segmentation in other categories in the respective section.